Paradigm Therapeutics Named Finalist for 2026 Prix Galien USA Award

MOUNT PLEASANT, S.C., Oct. 13, 2026 /CourierPR/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on rare diseases, has been named a finalist for the 2026 Prix Galien USA "Best Start-Up" Award for the second consecutive year. This recognition places the company among a select group of visionaries shaping the future of healthcare and medical innovation.

The award, America's premier prize in bioscience innovation, is managed by The Galien Foundation and rewards excellence in scientific innovations that address significant unmet medical needs. The 2026 Prix Galien USA Awards ceremony will be held on October 29, 2026, at the American Museum of Natural History in New York City.

SD-101 (Zorblesia™), a topical therapy developed by Paradigm Therapeutics, is the first treatment to receive the U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for treating wounds and lesions across the entire skin surface of patients with Epidermolysis Bullosa (EB). The therapy has also been granted Rare Pediatric Disease designation and Orphan Drug designation by the FDA, as well as previous Orphan Drug designation from the European Commission (EC).

SD-101 (Zorblesia™) is a topical cream that has demonstrated potential to provide improvement in treating the severe skin disruptions seen in patients across all EB subtypes. Results from completed Phase II and Phase III trials evaluated SD-101 in 217 pediatric and adult patients across the three major EB subtypes: Simplex, Dystrophic, and Junctional. The therapy was applied daily over the entire body, including to children as young as 28 days old, for three months. The data suggests a broad benefit in treating lesions and wounds across the entire body's skin surface while maintaining a favorable long-term safety profile.

Paradigm Therapeutics is a privately held, clinical-stage pharmaceutical company focused on developing innovative therapies to address critical medical needs in the treatment of rare diseases. The company's main focus is the treatment of Epidermolysis Bullosa (EB). SD-101 (Zorblesia™), its leading therapy for the treatment of skin effects in patients with Epidermolysis Bullosa, has completed Phase II and Phase III clinical trials. A confirmatory two-month study is being conducted in pediatric patients 28 days to 12 years old in patients across all EB subtypes.

Epidermolysis Bullosa is a rare, devastating genetic disorder causing very fragile skin that leads to severe skin blistering and open wounds often beginning at birth. There are no approved therapies that were developed to treat the entire skin surface of patients across all subtypes of EB patients, including wounds and lesional skin, which affects children and adults throughout their lifetimes. EB is a chronic disease, potentially disfiguring, and in some cases fatal. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma.

The company's goal is to provide this therapy to patients on a global basis, and it is working in parallel with potential partners to achieve this as quickly as possible. SD-101 (Zorblesia™) is a topical cream that requires no special handling and can be stored at room temperature.